Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT00630656 Completed - Severe Sepsis Clinical Trials

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

Start date: April 2008
Phase: Phase 2
Study type: Interventional

Study will evaluate the safety and potential benefit of recombinant human talactoferrin as an addition to the standard care of severe sepsis.

NCT ID: NCT00615862 Completed - Sepsis Clinical Trials

Relationship Between Alcohol Use Disorders and Cortisol Levels in Patients With Sepsis

Start date: March 2008
Phase: N/A
Study type: Observational

Patients with alcohol use disorders are often cared for in the intensive care unit (ICU). We estimate that close to half of the patients we care for in our ICU have alcohol use disorders. One of the reasons that patients with alcohol use disorders are frequently cared for in our ICU is because patients with alcohol use disorders are at higher risk of developing infections. The medical term for infections is sepsis. When an infection develops, patients with alcohol use disorders tend to get more severely ill compared to patients who do not have alcohol use disorders. Patients with alcohol use disorders are also at higher risk of dying when they develop severe infections. The purpose of this study is to determine why patients with alcohol use disorders become more severely ill when they develop infections. There are a number of reasons why this is possible. One reason is that a hormone called cortisol is higher in individuals with alcohol use disorders (who do not have infections). This hormone is also higher in patients who are at increased risk of dying from severe infections. One of the aims of this study is to see if cortisol levels are higher in patients with alcohol use disorders compared to those who do not have alcohol use disorders. Another reason why patients with alcohol use disorders are at increased risk of developing infections is because their immune system is not functioning properly. A second aim of this study is to see if certain markers of immune function are different in patients with alcohol use disorders compared to patients without alcohol use disorders. Patients with alcohol use disorders are also more likely to become confused when they are in the ICU. This condition is called delirium. Delirium is marked by abrupt onset of altered level of consciousness, disorganized thinking, and inattention that changes over time. Delirium tremens is one form of delirium. About 80% of our ICU patients develop delirium, and many patients who do not have alcohol use disorders develop the disorder as well. Patients with alcohol use disorders who have high cortisol levels have a higher chance of developing delirium compared to patients with normal cortisol levels. A third aim of this study is to examine the relationship between delirium and cortisol in both patients with and without alcohol use disorders.

NCT ID: NCT00608322 Completed - Sepsis Clinical Trials

Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis

Start date: August 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether inhaled nitric oxide is an effective treatment for microcirculatory dysfunction and acute organ system failure in the early stage of sepsis therapy.

NCT ID: NCT00568737 Completed - Sepsis Clinical Trials

The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death

Start date: November 2002
Phase: Phase 3
Study type: Interventional

Adult Patients with Severe Sepsis

NCT ID: NCT00561639 Completed - Sepsis Clinical Trials

Benefit of SeptiFast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis

SEPTIFAST
Start date: December 2007
Phase: N/A
Study type: Observational

A SpetiFast multiplex PCR kit has recently been placed on the market witch can evidence the DNA of 90% of micro-organisms (bacteria and fungus) implicated in sepsis. However, the clinical impact of being able to detect the DNA of these various agents is unknown. We propose to assess the benefit to patient care of the SeptiFast multiples PCR by answering three questions : 1/in patients with septic immunosuppression, does this kit evidence etiologic agents not revealed by classical methods? 2/Does the use of PCR results permit different diagnostic hypotheses to be considered? 3/Does having the SeptiFast results entail changes to the therapeutic plan?

NCT ID: NCT00559130 Completed - Sepsis Clinical Trials

Efficacy Study of CytoSorb Hemoperfusion Device on IL-6 Removal in ARDS/ALI Patients With Sepsis

Start date: November 2007
Phase: N/A
Study type: Interventional

The hypothesis of this study is use of CytoSorb hemoperfusion device as an adjunctive therapy to the standard of care in treating ARDS/ALI patients in the setting of sepsis will result in improved clearance of cytokines when compared to control patients receiving only the standard of care.

NCT ID: NCT00541827 Completed - Septic Shock Clinical Trials

Skeletal Muscle and Platelet Mitochondrial Dysfunction During Sepsis

Start date: October 2007
Phase: N/A
Study type: Observational

The primary aim of the study is to demonstrate that mitochondrial dysfunction occurs in both skeletal muscle and circulating platelets of severely septic and septic shock ICU-admitted patients. Secondary aims are to clarify the pathogenesis and the clinical relevance of mitochondrial damage during sepsis.

NCT ID: NCT00537693 Completed - Sepsis Clinical Trials

Cytokine Removal by CRRT in Pediatric Sepsis

Start date: September 2007
Phase: N/A
Study type: Interventional

This pilot study will compare the effect of diffusive versus convective Continuous Renal Replacement Therapy (CRRT) in children with sepsis who require CRRT. The hypothesis for the study is that convective forms of CRRT provide enhanced clearance of cytokines and improved clinical responses as compared to a diffusive CRRT modality.

NCT ID: NCT00534287 Completed - Septic Shock Clinical Trials

Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock

MaxSep
Start date: October 2007
Phase: Phase 3
Study type: Interventional

Severe sepsis and septic shock are diseases of infectious origin with a high risk of death. Antibiotic therapy is mandatory but it is unknown whether one antibiotic alone is sufficient for initial therapy. The purpose of this study is to compare a therapy with meropenem alone or the combination of meropenem plus moxifloxacin in the treatment of severe sepsis/ septic shock. Patients randomly receive one of the two treatments for at least 7 days but not longer than 14 days.

NCT ID: NCT00488917 Completed - Sepsis Clinical Trials

Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (the SELLIFA Study)

SELLIFA
Start date: June 2007
Phase: N/A
Study type: Observational

The purpose of the study is to determine the role of new biomarkers in the diagnosis of sepsis in critically-ill patients with liver failure and to correlate the prognosis of these patients with parameters of endothelial function and lipid metabolism.